Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma
| Autor: | Kazutaka Shiraishi, Yoshiaki Yushita, Yutaka Saito, Yuzo Minami, Hideki Sakai, Hiroshi Kanetake |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
medicine.medical_specialty Pathology Urology Acid Phosphatase Adenocarcinoma Epithelium Prostate medicine Carcinoma Humans Survival rate Aged Neoplasm Staging Aged 80 and over Epithelioma business.industry Prostatic Neoplasms Middle Aged Prognosis medicine.disease Immunohistochemistry female genital diseases and pregnancy complications medicine.anatomical_structure Oncology Prostatic acid phosphatase Multivariate Analysis business Immunostaining |
| Zdroj: | The Prostate. 19:265-272 |
| ISSN: | 1097-0045 0270-4137 |
| DOI: | 10.1002/pros.2990190307 |
| Popis: | To determine whether prostatic acid phosphatase (PAP) immunoreactivity in prostatic adenocarcinoma is a reliable prognostic factor, the PAP immunohistochemical distribution has been examined in 78 prostatic carcinoma cases. The intensity of PAP immunostaining was graded from 0 to 2, and the scores of the primary and the secondary staining patterns were added to assess the extent of the PAP expression in needle biopsy specimens. As a result, a higher cancer-specific survival rate was observed in patients showing a greater PAP immunostaining (P less than 0.01). Further, a multivariate analysis was made of possible prognostic factors (age, stage, Gleason score, serum PAP, PAP-immunostaining score, and the initial treatment) to estimate the extent of their impact on cancer-specific survival. Results have confirmed that the difference in PAP immunoreactivity is an excellent, independent prognostic factor for prostatic carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text